US SEC Trading Suspension Halt Orders — May 01, 2026

USA Trading Suspensions

6 high priority6 total filings analysed

Executive Summary

Across six 8-K filings in the USA Trading Suspensions stream, a dominant theme emerges of Nasdaq compliance challenges, with 5/6 companies facing deficiencies primarily in minimum bid price (4 cases) and market value of listed securities (1 case), alongside one audit committee issue; only Onfolio Holdings regained compliance, serving as a positive outlier. No period-over-period financial trends (YoY/QoQ revenue, margins) or insider trading activity reported in any filing, limiting quantitative portfolio comparisons, but aggregate sentiment is negative (5/6), with high materiality (avg 8.5/10) signaling acute delisting risks. Critical developments include Curis facing imminent suspension on May 6, 2026 unless appealed by May 4, while others have 180-day cure periods ending October 26-27, 2026; Greenidge has until April 15, 2027. Market implications point to heightened volatility, potential OTC delistings eroding liquidity and shareholder value for small-cap biotechs (Atara, Curis) and energy/tech firms (Greenidge, Rekor, CBAK). Portfolio-level pattern: 4/6 triggered by 30 consecutive business days below $1 bid price from mid-March to late April 2026, reflecting broad small-cap price pressure amid 2026 market dynamics. Onfolio's 10-day compliance from April 16-29, 2026 highlights potential for rapid turnarounds via price recovery.

Tracking the trend? Catch up on the prior US SEC Trading Suspension Halt Orders digest from April 24, 2026.

Investment Signals(10)

  • Regained Nasdaq bid price compliance ($1.00+ for 10 consecutive days April 16-29, 2026) after January 6 notice, resolving non-compliance; press release May 1 signals momentum

  • Greenidge Generation(NEUTRAL-BEARISH)

    Audit committee deficiency post-Kenneth Fearn resignation April 15, but cure period to April 15, 2027 (or earlier AGM); no immediate trading impact on GREE/GREEL, emerging growth status noted

  • MVLS below $50M for 30 days prior to April 30 notice; 180-day cure to October 27, 2026, considering Nasdaq Capital Market transfer

  • Curis(BEARISH)

    Direct delist determination April 27 for bid price < $1 over 30 days, under Discretionary Panel Monitor since Feb 3; suspension May 6 unless appeal by May 4

  • Bid price < $1 for 30 days March 13-April 24; 180-day compliance period to October 26, 2026, eyeing reverse split

  • Bid price < $1 for 30 days March 18-April 29; 180-day period to October 27, 2026, eligible for second 180-day grace

  • Onfolio Holdings(BULLISH OUTLIER)

    Sole positive amid 5 negatives; compliance post-4 month delinquency (Jan 6 notice) vs peers' ongoing issues

  • Curis vs Peers(BEARISH RELATIVE)

    No cure period due to prior monitor status, accelerating delist risk vs 180-day windows for Rekor/CBAK/Atara

  • Greenidge vs Bid Price Peers(MILDER BEARISH)

    Non-price deficiency (audit committee) with longer cure (to 2027) vs bid price cases' Oct 2026 deadlines

  • Aggregate Bid Price Failures(BEARISH SECTOR)

    4/6 companies below $1 for exactly 30 days in late Q2 2026 window, uniform trigger pattern

Risk Flags(8)

  • Scheduled suspension May 6, 2026 at open unless May 4 appeal; no cure period under prior Panel Monitor since Feb 3

  • $50M MVLS deficiency over 30 days to April 30; delisting post-Oct 27, 2026 if unmet, no compliance assurance

  • 30-day sub-$1 streak March 13-April 24; reverse split needed by early Oct 2026, second period conditional

  • Sub-$1 for March 18-April 29 period; potential delist post-Oct 27 + grace/appeal

  • Down to 2 independent directors post-April 15 resignation; cure to 2027 but Nasdaq notice April 29

  • Intends appeal to Hearings Panel but no success guarantee; direct delist path under Rule 5815(d)(4)(A)

  • May transfer to Capital Market but failure risks full delist + appeal

  • Aggregate/No Financial Backing[PORTFOLIO RISK]

    Zero filings report YoY/QoQ improvements, insider buys, or capital returns to offset compliance woes

Opportunities(8)

  • Freshly compliant May 1 announcement; potential re-rating post-delisting fear, monitor for sustained $1+ bids

  • May 4 appeal deadline to stay May 6 suspension; successful hearing could spark short-covering rally

  • Explicit consideration of reverse split before Oct 26 deadline; history shows post-split bounces in peers

  • Eligible for second 180 days post-initial Oct 27; battery sector tailwinds could aid price recovery

  • Nasdaq Capital Market shift option; lower standards could extend runway vs full delist

  • Plans new independent director in cure window to 2027; crypto/energy recovery could resolve easily

  • Short Delist Candidates(SHORT OPPORTUNITY)

    Curis (imminent May 6 risk) and bid-price laggards (avg 30-day sub-$1); OTC transition value erosion

  • Onfolio Peer Outperformance(OPPORTUNITY)

    Only regainer vs 5 strugglers; relative strength for long small-cap compliance turnaround basket

Sector Themes(5)

  • Bid Price Collapse in Small Caps(BEARISH)

    4/6 filings (Rekor, CBAK, Curis, Onfolio context) cite exact 30-day sub-$1 streaks March-April 2026; implies sector-wide price decay, delist cascade risk

  • Biotech Delisting Cluster[SECTOR RISK]

    Atara (MVLS) + Curis (bid price, imminent); both high materiality 9-10/10, no financial offsets noted

  • Energy/Tech Compliance Strain(MIXED)

    Greenidge (audit), Rekor (AI/traffic), CBAK (batteries) all deficient; longer cures but uniform Nasdaq pressure

  • Cure Period Uniformity(WATCH FOR EXECUTION)

    3/6 get 180 days to Oct 26-27, 2026 (Atara/Rekor/CBAK); reverse splits/appeals as common playbook

  • Positive Outlier Rarity(BULLISH SCARCE)

    1/6 regained (Onfolio); highlights scarcity of resolutions amid negative sentiment dominance

Watch List(7)

  • Monitor May 4 appeal filing and May 6 suspension status; Hearings Panel outcome critical [May 4-6, 2026]

  • Track if $1+ holds post-April 29 compliance; risk of re-deficiency [Ongoing from May 2026]

  • 10 consecutive $50M+ days needed by Oct 27; watch Capital Market transfer plans [By Oct 27, 2026]

  • Announcement or execution before 10 days pre-Oct 26; second period eligibility [By Oct 16, 2026]

  • Post-Oct 27 eligibility if other standards met; bid price recovery [Oct 27, 2026]

  • New independent for audit committee; next AGM or April 15, 2027 deadline [By April 15, 2027]

  • Aggregate Oct 2026 Cluster
    👁

    Atara/Rekor/CBAK compliance deadlines converge; sector volatility spike likely [Oct 26-27, 2026]

Filing Analyses(6)
Onfolio Holdings, Inc8-Kpositivemateriality 7/10

01-05-2026

Onfolio Holdings Inc. regained compliance with Nasdaq Listing Rule 5550(a)(2) after its common stock maintained a closing bid price of at least $1.00 per share for 10 consecutive business days from April 16 to April 29, 2026, resolving a prior non-compliance notice received on January 6, 2026. The company issued a press release on May 1, 2026, announcing this development. No other financial or operational metrics were reported.

  • ·Non-compliance notice dated January 6, 2026, for failure to maintain $1.00 minimum bid price over 30 consecutive business days
  • ·Compliance period: April 16, 2026 to April 29, 2026 (10 consecutive business days)
  • ·Date of earliest event reported: April 30, 2026
  • ·Filing date: May 1, 2026
Greenidge Generation Holdings Inc.8-Knegativemateriality 7/10

01-05-2026

Greenidge Generation Holdings Inc. is no longer in compliance with Nasdaq Listing Rule 5605(c)(2)(A), requiring an Audit Committee of at least three independent directors, following Kenneth Fearn's resignation from the Board and Audit Committee effective April 15, 2026. Nasdaq confirmed the non-compliance via notice on April 29, 2026, but granted a cure period until the earlier of the next annual stockholders' meeting or April 15, 2027 (or October 12, 2026 if the meeting precedes that date). The Company plans to appoint a new independent director and regain compliance within the period; the notice has no immediate impact on trading of Class A common stock (GREE) or 8.50% Senior Notes due 2026 (GREEL).

  • ·Company notified Nasdaq of non-compliance on April 23, 2026.
  • ·Emerging growth company status: Yes.
Atara Biotherapeutics, Inc.8-Knegativemateriality 9/10

01-05-2026

Atara Biotherapeutics, Inc. received a Nasdaq notice on April 30, 2026, for failing to meet the $50 million minimum market value of listed securities (MVLS) requirement under Nasdaq Listing Rule 5450(b)(2)(A), based on the prior 30 consecutive business days. The company has 180 calendar days until October 27, 2026, to regain compliance by achieving $50 million MVLS for at least 10 consecutive business days, with no immediate impact on trading of its common stock (ATRA) on the Nasdaq Global Select Market. However, there is no assurance of regaining compliance, and failure could lead to delisting, though an appeal option exists.

  • ·Compliance can be regained if MVLS closes at $50M or more for 10 consecutive business days before October 27, 2026; Nasdaq may require up to 20 days.
  • ·Company may evaluate transfer to Nasdaq Capital Market or other options to regain compliance.
  • ·In case of non-compliance by Compliance Date, Nasdaq will notify of delisting, with option to appeal to a Hearings Panel.
CURIS INC8-Knegativemateriality 10/10

01-05-2026

Curis, Inc. received a Delist Determination Letter from Nasdaq on April 27, 2026, notifying that its common stock (CRIS) bid price closed below the $1.00 minimum per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). Securities are scheduled for suspension and delisting from Nasdaq Capital Market at market open on May 6, 2026, unless the Company appeals by May 4, 2026, which it intends to do to stay the process. No assurance of success in appeal or continued listing.

  • ·Company under Discretionary Panel Monitor since February 3, 2026, per Listing Rule 5815(d)(4)(A); new deficiency triggers direct delist determination without cure period.
  • ·If appealed, hearing with initial or new Nasdaq Hearings Panel per Listing Rule 5815(d)(4)(C).
Rekor Systems, Inc.8-Knegativemateriality 9/10

01-05-2026

Rekor Systems, Inc. received a Nasdaq notice on April 27, 2026, for failing to meet the minimum bid price requirement of $1.00 per share, with closing prices below $1.00 for 30 consecutive business days from March 13 to April 24, 2026. The company has 180 calendar days until October 26, 2026, to regain compliance by achieving $1.00 closing bids for at least 10 consecutive business days, with trading continuing uninterrupted on Nasdaq under 'REKR'. While considering options like a reverse stock split, there is no assurance of regaining compliance, and a second 180-day period may be available if other listing standards are met.

  • ·Nasdaq Listing Rule 5810(c)(3)(A) governs the initial 180-day Compliance Period; reverse stock split, if pursued, must be completed no later than ten business days before October 26, 2026.
  • ·Eligibility for a Second Compliance Period requires meeting market value of publicly held shares and other initial listing standards (except bid price), plus written notice to Nasdaq.
CBAK Energy Technology, Inc.8-Knegativemateriality 9/10

01-05-2026

CBAK Energy Technology, Inc. received a Nasdaq notice on April 30, 2026, for failing to meet the minimum bid price requirement of $1.00 per share under Listing Rule 5550(a)(2), based on closing bid prices over 30 consecutive business days from March 18 to April 29, 2026. The Company has 180 calendar days until October 27, 2026, to regain compliance by achieving a $1.00 closing bid price for 10 consecutive business days, with trading of CBAT continuing uninterrupted on Nasdaq Capital Market. Non-compliance may lead to delisting after a potential additional 180-day grace period and appeal opportunity.

  • ·Nasdaq Listing Rule 5810(c)(3)(A) governs the 180-day compliance period and potential second 180-day grace period.
  • ·Company eligible to appeal delisting determination to a Hearings Panel if non-compliance persists.
  • ·Securities registered: Common Stock, $0.001 par value, ticker CBAT on Nasdaq Capital Market.

Get daily alerts with 10 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 6 filings

More from: US SEC Trading Suspension Halt Orders

🇺🇸 More from United States

View all →